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Reply
To the Editor:
The letter from Drs McKenzie and Szepietowski in connection
with our article (Hu et al, 2000) extended our observation and
discussed the probable function of LIF in skin. The letter is helpful
in understanding the cytokine network in skin. We agree with
most of their viewpoints.
In the letter, however, they wrote: Hu et al ``recorded no or
negligible LIF immunoreactivity in disease control skin'', whereas
their group ``always observed LIF immunoreactivity in normal
skin''. Quantitative comparison should be taken under the same
conditions. In McKenzie's report (Paglis et al, 1996), the LIF
immunostaining in normal skin seemed strong. But they used
different immunohistochemical conditions from ours, by which the
intensity of immunostain will be strongly affected. We used a
different antibody (an af®nity-puri®ed polyclonal antibody against
the LIF peptide, N-18, Santa Cruz, CA), a different immunor-
eactive condition (concentration of primary antibody 1 mg per ml,
incubated for 12 h), and a different section method (paraf®n-
embedded section). The normal skin samples they used were
obtained from surgery patients, and transported in DMEM medium
to the laboratory. Traumatic reaction might occur in this step,
resulting in the elevation of cytokine concentrations (including
LIF). On the contrary, we ®xed all the biopsy samples immediately
in formalin. Furthermore, the ethnic difference should also be
considered as an effective factor.
In our article, we compared LIF immunoreactivity in biopsied
skins between ALS and other neurodegenerative disease controls.
For ethical reasons, we did not include any biopsied skin specimens
from normal subjects. We could not know how strong the LIF
immunoreactivity was in normal skin, and whether immunor-
eactivity in ALS skin was just the same as that in normal skin.
Nevertheless, we did not negate the LIF immunoreactivity in the
skin of disease control. We also thought that a low level of LIF
immunoreactivity in normal skin was reasonable. We emphasized
that ALS patients expressed far more LIF in skin than the disease
control subjects did. In our study, the immunoreactivities in the
skins of ALS cases and controls were detected simultaneously under
the same experimental conditions. The immunoreactive intensity
was expressed as optical density (OD, arbitrary unit). The OD of
ALS skins ranged from 9.0 to 1.9, while that of disease controls
ranged from 1.8 to 0.4. Although the immunoreactive pattern in
ALS with an OD of 1.9 was similar to that in disease-control with
an OD of 1.8, the ALS group was signi®cantly different from the
disease control group statistically. Furthermore, we found that the
OD in ALS showed a progressive increase in relation to duration of
the illness (r = 0.82, p < 0.01), suggesting that OD in long duration
patients should be higher than that in normal controls. The OD in
ALS patients with a duration of 3.2 y was 9.0, while that of 0.4 y
was only 1.8. We do not believe OD in normal skin could be as
high as 9.0, unless they were proved by simultaneous and
quantitative comparison.
Jianguo Hu, Seitsu Ono*
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Limited Concordance Between ``Oakmoss'' and Colophony in
Clinical Patch Testing
To the Editor
Recently, Lepoittevin et al (2000) reported on the detection of
various resin acids in ``treemoss'' perfume extracts, some of them
identical to those found in colophony and its oxidation products,
respectively. Furthermore, a considerable contamination of ``oak-
moss'' raw material, especially the material used by Trolab
(Reinbek, Germany) for manufacturing ``oakmoss'' patch test
material, with these resin acids was found (5.6% resin acids and
0.7% 7-oxo-dehydroabietic acid, a sensitizing oxidation product of
colophony). Accordingly, the majority of their 17 patients
sensitized to colophony not only reacted to ``treemoss'' (n = 12),
but also to ``oakmoss'' by Trolab (n = 9), but rarely to ``oakmoss''
by Chemotechnique (Malmo, Sweden, n = 2) containing less than
0.4% wt/wt resin acids.
To put these challenging results pointing to a tremendous
potential for misdiagnosis into the perspective of clinical patch
testing with ``oakmoss'', national surveillance data of the IVDK
(http://www.ivdk.gwdg.de) collected between January 1992 and
December 1999, in the 34 participating centers (see footnote 1)
were analyzed. Test substances were supplied by Trolab, results
based on readings at 72 h following the standards of the
International Contact Dermatitis Research Group. In the above
period, 67,306 patients were patch tested to colophony (20% in
petrolatum), which is contained in the standard test series, with
1433 (2.1%) weakly positive (``+''), 1154 (1.7%) strongly
positive (``++'' or ``+++'') and 697 (1.0%) equivocal (``?'')
or, rarely, irritant reactions. At the same time, 12,823 patients
were patch tested to ``oakmoss'' (1% in petrolatum, the same as
used by Lepoittevin et al, 2000), which is included in the
fragrances series and two other special series. These are tested in
a more focussed way, often as a breakdown of the fragrance
mix in case of a positive reaction. Nearly all patients (98.4%)
were also tested with colophony. Results obtained in this
subgroup (n = 12,614) are presented in the format of a 5 3 5
contingency table (Table I) showing the joint distribution of
patch test reactions to both test substances. Altogether 27.0% of
all persons allergic to colophony reacted positively (``+'' to
``+++'') to ``oakmoss'', whereas only 5.5% positive reactions to
``oakmoss'' were found in the rest. This ®nding points to a
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substantial degree of association between the two patch tests
(relative risk: 4.89, 95% con®dence interval (CI): 4.22±5.67).
Interestingly, the proportion of ``oakmoss'' positive patients
(``+'' to ``+++'') increased from 5.4% in patients not reacting
to colophony, to 14.7% in those reacting with erythema only
(``?''), to 19.4% in those with a ``+'' reaction, to 30.0% in
those with a ``++'' reaction, and to 53.3% in those with very
strong (``+++'') reactions to colophony (Cochran-Armitage
trend test: p < 0.0001), see Table I. To further address the
question of concordance, i.e., whether the two tests yield more
or less identical results, we calculated Cohen's kappa (Cohen,
1960). This standard measure in such analyses quanti®es the
chance-corrected proportion of agreement between two discrete
ratings and gives a more informative quantitative summarization
of concordance than the crude proportion of agreement for
skewed distributions of ratings as in this case (Fleiss, 1981).
Although 87.1% of the patients showed identical patch test
results for both tests, the kappa value is only 0.13 (95% CI:
0.11±0.15) indicating a very low degree of concordance beyond
chance.
While the analytical results of Lepoittevin et al (2000) give
some insight into the pitfalls in patch testing (with natural
materials), we have some reservations concerning the practical
conclusions that can be drawn from these observations. First of
all, the magnitude of the problem in practice and its relevance
seems to be considerably smaller than indicated by their study.
Actually, the small sample size (n = 17) makes these results quite
imprecise (the exact 95% CI accompanying 52.9% as derived
from ``9 out of 17'' is 27.8%±77.0%, the lower limit being not
far away from our estimate of 27.0% (exact 95% CI: 23.6%±
30.6%). Concerning cross-reactivity, concordance beyond
chance is very limited considering the whole group of patients.
The strong association between the degree of sensitization to
colophony and ``oakmoss'' reactivity, however, could support
the notion of minute traces of resin acids present in ``oakmoss''
being capable of eliciting a positive reaction at least in patients
with extreme sensitivity to colophony. Of course, nonspeci®c
mechanisms like the ``angry back syndrome'' must also be
considered if any very strong reaction is observed, and, indeed
(very) strong reactions are generally associated with an increased
number of concomitant patch test reactions (J. Brasch, personal
communication, 2000).
Last but not least the possibility of concurrent sensitization to
``oakmoss'' and ``treemoss'', which are used together in
perfumes (Dahlquist and Fregert, 1980) ± intentionally or
unintentionally (by using ``oakmoss'' raw material that is often
blended with the cheaper ``treemoss'' material) ± had not been
taken into account by Lepoittevin et al (2000). In principle,
highly puri®ed patch test material should be used to standardize
patch testing wherever possible ± and necessary. The question
remains: is pure ``oakmoss'' patch test material a necessity, in
view of the largely combined clinical exposure to ``oakmoss''
and ``treemoss'', or, conversely, is not ``contaminated'' patch test
material even more adequate to sensitively diagnose relevant
sensitization?
Wolfgang Uter, Olaf Gefeller,* Johannes Geier, Axel Schnuch
(for the IVDK1)
Information Network of Departments of Dermatology (IVDK),
Georg August University, Department of Dermatology,
GoÈttingen, Germany
*Department of Medical Informatics,
Biometry and Epidemiology,
Friedrich-Alexander-University Erlangen-NuÈrnberg,
Erlangen, Germany
REFERENCES
Cohen J: A coef®cient of agreement for nominal scales. Educational Psychol
Measurement 20:37±46, 1960
Dahlquist I, Fregert S: Contact allergy to atranorin in lichens and perfumes. Contact
Dermatitis 2:111±119, 1980
Fleiss JL: Statistical Methods for Rates and Proportions, 2nd edn. New York: Wiley, 1981
Lepoittevin J-P, Meschkat E, Huygens S, Goossens A: Presence of resin acids in
``oakmoss'' patch test material: a source of misdiagnosis? J Invest Dermatol
115:129±130, 2000
Reply
To the Editor:
We read with interest the letter from Uter et al. (2001) on the
concordance between ``oakmoss'' and colophony in clinical patch
testing.
The aim of our paper (Lepoittevin et al. 2000) was to see if patients
with a well-established allergy to colophony could react when tested
with usual concentrations of ``oakmoss'' due to the presence of resin
acids and their oxidation products. The 17 patients included in our
study were therefore selected on the base of their known past and
relevant allergy to colophony. The aim of our study was never to
evaluate the percentage of concordance between oakmoss and
colophony on a large population but to draw attention to a possible
misdiagnosis due to the presence of impurities in patch test material.
Table I. Patch test results with colophony (20% pet.) and
``oakmoss'' (1% pet., both by Trolab) in 12614 patients
between 1992 and 1999
``Oakmoss''
Sum/(%)
Colophony neg. ?/IR + ++ +++ Colophony
neg. 10905 253 416 164 55 11793
(93.5%)
?/IR 134 17 19 5 2 177
(1.4%)
+ 261 21 41 20 7 350
(2.8%)
++ 130 22 45 20 0 217
(1.7%)
+++ 34 2 15 18 8 77
(0.6%)
Sum/(%) 11464 315 536 227 72 12614
``Oakmoss'' (90.9%) (2.5%) (4.2%) (1.8%) (0.6%) (100.0%)
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1Centers of the IVDK contributing to this analysis (in alphabetical order):
Aachen (H. Dickel), Augsburg (O. Hirschsteiner, A. Ludwig), Berlin B.
Franklin (B. Tebbe, R. Treudler), Berlin ChariteÂ (B. Laubstein, J. Grabbe,
T. Zuberbier), Berlin UKRV (J. Grabbe, T. Zuberbier), Bochum (C.
Szliska), Dortmund (P.J. Frosch, B. Pilz, C. Pirker), Dresden (G. Richter),
Duisburg (J. Schaller), Erlangen (K.P. Peters, M. Fartasch), Essen (H.-M.
Ockenfels, U. Hillen), GoÈttingen (Th. Fuchs), Graz (W. Aberer, B.
KraÈnke), Halle (G. Gaber, D. LuÈbbe), Hamburg (M. Kiehn, D. Vieluf),
Heidelberg (A. Schulze-Dirks, M. Hartmann), Homburg/Saar (P. Koch),
Jena (M. Gebhardt, A. Bauer), Kiel (J. Brasch), LuÈbeck (J. Kreusch, J.
Grabbe), Magdeburg (U. Jappe, E. Weisshaar), Mainz (D. Becker),
Mannheim (C. Bayerl), Marburg (I. Effendy), MuÈnchen LMU (F. Enders,
B. Przybilla), MuÈnchen Schwabing (M. Agathos), MuÈnchen TU (J.
Rakoski), NuÈrnberg (I. MuÈller), OsnabruÈck (W. Uter), Rostock (H.
Heise), TuÈbingen (G. Lischka), Ulm (H. Gall), Wuppertal (O. Mainusch, J.
Raguz).
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